ライフサイエンスコーパス: fetoprotein

1 for alkaline phosphatase, P<.0001 for alpha-fetoprotein).

2 umors that express increased levels of alpha-fetoprotein.

3 MELD score, HCC size, HCC number, and alpha-fetoprotein.

4 vasion, metastasis, serum albumin, and alpha-fetoprotein.

5 ression of fetal liver genes including alpha-fetoprotein.

6 omitantly with increased expression of alpha-fetoprotein.

7 antigen, cytokeratin (CK) 7, CK20, and alpha-fetoprotein.

8 cytes expressing the oncofetal marker, alpha-fetoprotein.

9 epatic neoplasia and increase in serum alpha-fetoprotein.

10 tive of tumor burden or serum level of alpha-fetoprotein.

11 m increase [1.04-1.11]; p<0.0001), log alpha-fetoprotein (1.10 per unit increase [1.02-1.20]; p=0.018

12 patients with an elevated pretreatment alpha-fetoprotein, 85% were found to have declining alpha-feto

13 homogeneous liquid-phase detection of alpha-fetoprotein, a common tumor marker, the system shows a g

14 tion of beta-catenin and expression of alpha-fetoprotein, a prognostic marker of hepatocellular carci

15 -fetoprotein (MSAFP) or amniotic fluid alpha-fetoprotein (AFAFP) levels or abnormalities visualized o

16 Elevated alpha-fetoprotein (AFP) >/= 10,000 ng/mL was associated with w

17 GCTs were resected and monitored with alpha-fetoprotein (AFP) ("watch-and-wait" approach).

18 ysis for patients with a high level of alpha-fetoprotein (AFP) (>100 ng/dL) was conducted.

19 ker A6 (94.57% +/- 0.033%), as well as alpha-fetoprotein (AFP) (75.92% +/- 0.071%).

20 apy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropi

21 were identified: cells expressing both alpha-fetoprotein (AFP) and albumin, but not CK-19; cells expr

22 Mean preoperative serum alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin

23 We used two model biomarkers [alpha-fetoprotein (AFP) and cancer antigen 125 (CA125)] to dem

24 s study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP

25 had twice yearly screening with serum alpha-fetoprotein (AFP) and hepatic ultrasound than in patient

26 e of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic gonadotrophin (HCG

27 vels of alkaline phosphatase (ALP) and alpha-fetoprotein (AFP) and lower level of alanine aminotransf

28 HCC surveillance with alpha-fetoprotein (AFP) and ultrasonography has been recommend

29 We identified alpha-fetoprotein (AFP) and ultrasound tests performed for HCC

30 els of mRNA and/or protein for WT1 and alpha-fetoprotein (AFP) are increased.

31 Serum levels of alpha-fetoprotein (AFP) are influenced not only by the presenc

32 In addition, we have identified the alpha-fetoprotein (AFP) as a novel downstream target of NF-kap

33 Twenty-three patients had elevated alpha-fetoprotein (AFP) at diagnosis.

34 ansplant (RETREAT), which incorporates alpha-fetoprotein (AFP) at liver transplantation (LT), microva

35 ate quantitation of biomarkers such as alpha-fetoprotein (AFP) can be a key aspect of early stage can

36 ears, 3-7 years, and 8 years or older; alpha fetoprotein (AFP) concentration of 100 ng/mL or lower an

37 e HCC-associated self/tumor antigen of alpha-fetoprotein (AFP) could be engineered to create an effec

38 g-positive Alaska native carriers with alpha-fetoprotein (AFP) determinations every 6 months.

39 We previously showed that mouse alpha-fetoprotein (AFP) enhancer 3 activity is highly restrict

40 on under the control of an albumin and alpha-fetoprotein (AFP) enhancer and promoter (AFP-Notch intra

41 Although alpha-fetoprotein (Afp) falls into this class of genes, as it

42 wn that p53 represses hepatic-specific alpha-fetoprotein (AFP) gene expression by direct interaction

43 Aberrant expression of the alpha-fetoprotein (AFP) gene is a diagnostic tumor marker of h

44 The alpha-fetoprotein (AFP) gene is an important model of developm

45 The alpha-fetoprotein (AFP) gene is expressed abundantly in the fe

46 The alpha-fetoprotein (AFP) gene is transcribed at high levels in

47 e promoter of the hepatic tumor marker alpha-fetoprotein (AFP) gene.

48 zed methylation of the rat albumin and alpha-fetoprotein (AFP) genes by hydridizing labeled cDNA clon

49 tumor diameter of 3 to 5 cm and serum alpha fetoprotein (AFP) greater than 100 ng/mL at transplant y

50 For decades, alpha-fetoprotein (AFP) has been used as a differentiation mar

51 neutrophil-lymphocyte ratio (NLR) and alpha-fetoprotein (AFP) have been associated with recurrence r

52 ce status, Child-Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual survival.

53 to be more sensitive and specific than Alpha-fetoprotein (AFP) in the diagnosis of HCC among the Whit

54 alpha-Fetoprotein (AFP) independently predicted tumor recurren

55 Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carc

56 Serum alpha-fetoprotein (AFP) is a biomarker for hepatocellular carc

57 alpha-Fetoprotein (AFP) is a potential target for immunotherap

58 The L3 isoform of alpha-fetoprotein (AFP) is a specific marker for hepatocellula

59 alpha-Fetoprotein (AFP) is an oncofetal Ag and has intrinsic i

60 alpha-fetoprotein (AFP) is an oncofetal Ag that is highly expr

61 Alpha-fetoprotein (AFP) is considered to be an indicator of tu

62 ensitive detection of cancer biomarker alpha-fetoprotein (AFP) is described that uses a graphene shee

63 alpha-Fetoprotein (AFP) is frequently used as a diagnostic mar

64 d expression of the hepatoblast marker alpha-fetoprotein (Afp) is lost.

65 Although serum alpha-fetoprotein (AFP) is often used to detect hepatocellular

66 HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose.

67 Alpha-fetoprotein (AFP) is widely used as a surveillance test

68 An alpha-fetoprotein (AFP) level > 1,000 ng/mL, total tumor diame

69 hort of 721 patients (542 men), median alpha-fetoprotein (AFP) level at the time of LT was 8.3 ng/mL;

70 staging system, tumor size, and serum alpha-fetoprotein (AFP) level were investigated using Cox prop

71 mph node metastases and a rising serum alpha-fetoprotein (AFP) level.

72 Nonetheless, serial measurement of alpha-fetoprotein (AFP) levels in serum and hepatic ultrasound

73 in terms of toxicity, tumor response, alpha-fetoprotein (AFP) levels, and serum arginine levels.

74 with tumor histology and pretransplant alpha-fetoprotein (AFP) levels.

75 dentify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular carcinom

76 Alpha-fetoprotein (AFP) represents a classical model system to

77 group has shown that a rising natural alpha-fetoprotein (AFP) slope (NAS) correlates with tumor char

78 Although surveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm, downst

79 alpha-Fetoprotein (AFP) transcription is activated early in he

80 r p53 in the regulation of the hepatic alpha-fetoprotein (AFP) tumor marker gene.

81 nt assay was developed to detect human alpha-fetoprotein (AFP) using carbon dots (C-Dots).

82 Serum alpha-fetoprotein (AFP) values in patients with and those with

83 In 17 patients the baseline serum alpha-fetoprotein (AFP) was >or= 1,000 ng/mL; in four of these

84 e the device under optimal conditions, alpha-fetoprotein (AFP) was detected at a limit of detection o

85 Remarkably, expression of alpha-fetoprotein (AFP) was highly correlated with the molecul

86 nique serum levels of IL-6, IL-10, and alpha fetoprotein (AFP) were evaluated in all groups.

87 Levels of human alpha-fetoprotein (AFP) were monitored in the serum of animals

88 epatitis B surface antigen (HBsAg) and alpha-fetoprotein (AFP) with the lowest concentration of naked

89 ion molecule (EpCAM)(+) HCC cells from alpha-fetoprotein (AFP)(+) tumors with cancer stem/progenitor

90 s12979860), serum 25OH-vitamin D, serum alfa-fetoprotein (AFP)) were performed on a cohort of 200 Egy

91 h activated Wnt signaling occupying an alpha-fetoprotein (AFP)+/cytokeratin-19 (CK-19)-positive proge

92 As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular

93 alpha-Fetoprotein (AFP), a tumor marker currently used for the

94 hepatic associated gene expression of alpha-fetoprotein (AFP), Albumin (Alb), Glucose-6-phosphatase

95 inoembryonic antigen (CEA), bilirubin, alpha fetoprotein (AFP), and c-reactive protein (CRP) were ide

96 some potential advantages compared to alpha-fetoprotein (AFP), but its role in the context of alcoho

97 rkers: carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), cancer antigen 125 (CA125), and carbo

98 The fetal hepatocytes expressed alpha-fetoprotein (AFP), cytokeratin (CK) 19, albumin, and oth

99 erlapping peptides spanning the entire alpha-fetoprotein (AFP), glypican-3 (GPC-3), melanoma-associat

100 The conventional serum marker for HB, alpha-fetoprotein (AFP), has its limitations.

101 or markers of visceral endoderm (DAB2, alpha-fetoprotein (AFP), HNF4).

102 ctor required for HSC homing, and also alpha-fetoprotein (AFP), indicating that they are fetal hepati

103 atocellular carcinoma (HCC) biomarkers alpha-fetoprotein (Afp), insulin-like growth factor 2 (Igf2),

104 They are negative for alpha-fetoprotein (AFP), intercellular adhesion molecule (ICAM

105 y associated with elevated circulating alpha-fetoprotein (AFP), low rate of necrosis/fibrosis after t

106 Serum alpha-fetoprotein (AFP), normally highly expressed in the live

107 dominant and subdominant epitopes from alpha fetoprotein (AFP), restricted by HLA-A*0201, which are r

108 A expression was associated with serum alpha-fetoprotein (AFP), tumor-node-metastasis (TNM) stage, an

109 this approach, an aptamer specific to alpha-fetoprotein (AFP), which is a biomarker for liver cancer

110 lymer (MIP) for trace level sensing of alpha-fetoprotein (AFP), which is a well know cancer biomarker

111 (MELD-Na), tumour burden score (TBS), alpha-fetoprotein (AFP), year of transplantation, underlying c

112 alpha fetoprotein (AFP)-derived peptide epitopes can be recogn

113 pmental repression of the tumor marker alpha-fetoprotein (AFP).

114 mplication by determining the level of alpha-fetoprotein (AFP).

115 19, albumin +/-, and are negative for alpha-fetoprotein (AFP).

116 HCC in Japanese patients compared with alpha-fetoprotein (AFP).

117 gulation of the HCC tumor marker gene, alpha-fetoprotein (AFP).

118 fic silencing of the tumor marker gene alpha-fetoprotein (AFP).

119 nsitive detection of cancer biomarker, alpha-fetoprotein (AFP).

120 otal tumor volume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP; </=400 ng/mL) score.

121 ence as well as patients with negative alpha-fetoprotein (AFP; n = 1), resulting in 24 patients and 5

122 ntly identified HCC subtypes (EpCAM(+) alpha-fetoprotein [AFP(+)] HCC and EpCAM(-) AFP(-) HCC).

123 associated self-antigens (for example, alpha-fetoprotein [AFP]).

124 ibodies specific for epithelial cells (alpha-fetoprotein [AFP], albumin [ALB], pancytokeratin [PanCK]

125 l recommended measuring three markers (alpha-fetoprotein [AFP], human chorionic gonadotropin [hCG], a

126 The vast majority of alpha fetoprotein(+), albumin(+), cytokine-19(+), and E-cadher

127 (80%) patients with elevated markers (alpha-fetoprotein alone in three, alpha-fetoprotein and beta h

128 lpha-fetoprotein and ferritin or serum alpha-fetoprotein alone, including four with coagulopathy (int

129 n gene family is comprised of albumin, alpha-fetoprotein, alpha-albumin (afamin), and the more distan

130 the serum transport proteins albumin, alpha-fetoprotein, alpha-albumin, and vitamin D-binding protei

131 nogen, fibronectin, transthyretin, and alpha-fetoprotein, an essential feature for functional HE.

132 t this enhancer region is required for alpha-fetoprotein and albumin activation early in liver develo

133 re analyzed by immunocitochemistry for alpha-fetoprotein and albumin expression, qPCR for hepatocyte

134 that RNA polymerase II loading on the alpha-fetoprotein and albumin promoters is reduced in the abse

135 ed (45-70%) for cells that express the alpha-fetoprotein and albumin proteins.

136 er of a cluster that includes albumin, alpha-fetoprotein and alpha-albumin genes.

137 e genes, particularly that of albumin, alpha-fetoprotein and alpha-albumin, and their liver-specific

138 ers (alpha-fetoprotein alone in three, alpha-fetoprotein and beta human chorionic gonadotropin in one

139 er than normal concentrations of serum alpha-fetoprotein and ferritin or serum alpha-fetoprotein alon

140 The prognostic information provided by alpha-fetoprotein and human chorionic gonadotrophin in the man

141 Serum tumor markers alpha-fetoprotein and human chorionic gonadotrophin were corre

142 142 mEq/L [134-142 mmol/L]), and serum alpha-fetoprotein and human chorionic gonadotropin levels were

143 Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of Txnip-d

144 with induction of the human HCC marker alpha-fetoprotein and the stem cell marker CD133.

145 ond-trimester levels of maternal serum alpha-fetoprotein and the subsequent risk of SIDS.

146 l transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt export pump

147 with slow serum tumor marker decline (alpha-fetoprotein and/or human chorionic gonadotrophin) during

148 rcinoembryonic antigen, CK7, CK20, and alpha-fetoprotein) and in the distinction from cholangiocarcin

149 ession/coexpression of DCAMKL-1, CK19, alpha-fetoprotein, and active c-Src.

150 liver phenotype: albumin, transferrin, alpha-fetoprotein, and alpha1-antitrypsin.

151 he expression of biliary cytokeratins, alpha-fetoprotein, and c-Met by FIHC.

152 ge liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor diameters; were more l

153 eted hepatic proteins such as Albumin, Alpha Fetoprotein, and Fibrinogen, metabolized ammonia, and di

154 Age, LRT status, serum alpha1-fetoprotein, and microvascular invasion were independent

155 xpressed both donor marker (DPPIV) and alpha-fetoprotein, and some differentiated into hepatocytes.

156 bilirubin, albumin, prothrombin time, alpha-fetoprotein, and tumor number, which were incorporated i

157 ion; levels of bilirubin, albumin, and alpha-fetoprotein; and WHO/EASL response rate predicted surviv

158 with HBV had larger tumors and higher alpha-fetoprotein but less satellites and macrovascular invasi

159 g cytoplasmic/nuclear beta-catenin and alpha-fetoprotein but not CK19, HNF1beta, or Trop-2.

160 okeratin 19 (CK19), transthyretin, and alpha-fetoprotein by day 7, and expressed CK18, HNF-4, and HNF

161 , primary site, treatment, and elevated alfa fetoprotein by univariate and multivariate analysis.

162 met+, SSEA-4+, CK18+, CK19+, albumin-, alpha-fetoprotein-, CD44h+, and vimentin+.

163 ignificantly different among the three alpha-fetoprotein classes (P = 0.493).

164 ording to randomising centre and serum alpha-fetoprotein concentration (<400 ng/mL and >/=400 ng/mL).

165 d serum human chorionic gonadotropin or alfa-fetoprotein concentrations that matched International Ge

166 ients' human chorionic gonadotropin and alfa-fetoprotein concentrations were measured at day 18-21.

167 ine in human chorionic gonadotropin and alfa-fetoprotein continued BEP (Fav-BEP group) for 3 additona

168 was assessed by expression of albumin, alpha-fetoprotein, cytochrome P4502E1, cytokeratin-18, type-1

169 Rat ED14 FLSPC are alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)

170 ha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19(-) and contain all of the

171 and embryonal carcinomas positive for alpha-fetoprotein, cytokeratin AE1/AE3, and CD30.

172 kinase-like-1 (DCAMKL-1), Lgr5, CD133, alpha-fetoprotein, cytokeratin-19 (CK19), Lin28, and c-Myc.

173 zones were simultaneously positive for alpha-fetoprotein, cytokeratin-19, and c-kit, indicating their

174 press the classical oval cell markers (alpha-fetoprotein, cytokeratin-19, OV-1 antigen, a6 integrin,

175 In conclusion, alpha-fetoprotein-derived peptide appears to be a novel agent

176 when the values of known serum markers alpha fetoprotein, des-gamma carboxyprothrombin, and GP73 were

177 A raised maternal serum level of alpha-fetoprotein during the second trimester of pregnancy is

178 aced the endodermal enhancers with the alpha-fetoprotein endodermal enhancers (H19Afp).

179 g Cre-recombinase under control of the alpha fetoprotein enhancer and albumin promoter.

180 To directly examine whether the alpha-fetoprotein enhancer region could regulate the albumin g

181 he control of the albumin promoter and alpha-fetoprotein enhancer to ablate Jag1 in hepatoblasts.

182 ression of vimentin, beta-III tubulin, alpha-fetoprotein, eomesodermin, HEB, ARNT, and FoxD3 as well

183 bdominal computed tomography and serum alpha-fetoprotein every 6 months.

184 ell proliferation and a lower level of alpha-fetoprotein expression as compared with control animals.

185 duced albumin expression and decreased alpha-fetoprotein expression in HepG2 cells, which suggests th

186 s of the similarities between Gpc3 and alpha-fetoprotein expression in the liver, we reasoned that co

187 pression caused a dramatic decrease in alpha-fetoprotein expression, implying impaired oval cell acti

188 ning (absent or diffuse), and variable alpha-fetoprotein expression.

189 spalt-like transcription factor 4, and alpha-fetoprotein expression; and high coordinated expression

190 atocyte nuclear factor 4 (HNF-4), HNF-3, and fetoprotein factor to the precore/core promoter enhancer

191 The albumin and alpha-fetoprotein genes are adjacent and express closely relat

192 ession of endogenous SAA, albumin, and alpha-fetoprotein genes.

193 n patients older than 60 years, serum alpha1-fetoprotein greater than 400 mg/L, bilobar distribution,

194 8.5 years); 109 were female; and 99 had alfa fetoprotein > or = 10,000.

195 ownstaging group included pretreatment alpha-fetoprotein >/=1,000 ng/mL (multivariate hazard ratio [H

196 ing treatment failure was pretreatment alpha-fetoprotein >1,000 ng/mL.

197 identified age <65 years (P = 0.038), alpha-fetoprotein >200 ng/mL (P = 0.04), and vascular invasion

198 nvasion, exceeding Milan criteria, and alpha-fetoprotein>200 ng/mL.

199 yonic stem (ES) cells expressing human alpha-fetoprotein (hAFP) under control of the endogenous promo

200 tumors, presence of metastases, serum alpha-Fetoprotein, hepatitis serologies, severity of hepatic d

201 They also expressed alpha-fetoprotein, hepatocyte nuclear factor-4a, and a metabol

202 inical diagnostic application, such as alpha-fetoprotein in liver carcinoma, and kallikreins 6 and 10

203 ate the prognostic usefulness of serum alpha-fetoprotein in patients with well-compensated cirrhosis,

204 ty of des-gamma-carboxyprothrombin and alpha-fetoprotein in the diagnosis of hepatocellular carcinoma

205 a clinically relevant assay to detect alpha-fetoprotein, in which a 42-fold enhancement to sensitivi

206 he proposed Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score was the best pred

207 /alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (

208 Alpha-fetoprotein is a tumor marker that has been used for sur

209 Alpha-fetoprotein is the most widely used tumor marker, but ha

210 atio, 1.61; 95% CI: 1.3-2.1) and serum alpha-fetoprotein level >/=455 ng/mL (hazard ratio, 2.15; 95%

211 nts with larger (3-5 cm) tumors, serum alpha-fetoprotein level >/=455 ng/mL, or a MELD score >/=20 ha

212 hotic liver in the presence of a serum alpha-fetoprotein level >400 ng/mL also is diagnostic.

213 An alpha-fetoprotein level >500 ng/mL predicted poorer outcomes f

214 ed significant effects of pretreatment alpha-fetoprotein level (P = .03) and ADC ratio (P < .0001) on

215 nal normalized ratio greater than 1.1, alpha-fetoprotein level greater than 20 ng/mL, multiple tumors

216 A preablative serum alpha-fetoprotein level higher than 200 ng/mL (hazard ratio: 9

217 candidates for liver transplantation; alpha-fetoprotein level limitations should be incorporated in

218 nge, 13-60 U/L [0.21-1.0 mukat/L]), an alpha-fetoprotein level of 3.81 ng/ mL (normal range, 0-9 ng/m

219 udies were significant for an elevated alpha-fetoprotein level of 7051 ng/ml and mild anemia.

220 ar invasion, extrahepatic disease, and alpha-fetoprotein level to best supportive care plus oral rego

221 slightly depressed at 121,000 muL, and alpha-fetoprotein level was 89 mug/L.

222 hieved in 10 patients (83.3%), and the alpha-fetoprotein level was also decreased to normal in these

223 Serum alpha-fetoprotein level was elevated in 26 patients.

224 arkers for ovarian cancer were normal (alpha-fetoprotein level, 1.6 microg/L; Ca-125 level, 15 U/mL;

225 cal factors (age, gender, preoperative alpha-fetoprotein level, hepatitis serology, number of tumors

226 onment also correlated with high serum alpha-fetoprotein levels (P < 0.001), macrovascular invasion (

227 scores (P = .003), higher pretreatment alpha-fetoprotein levels (P = .04), and a greater number of pr

228 It is unknown whether alpha-fetoprotein levels also predict the risk of SIDS.

229 etween second-trimester maternal serum alpha-fetoprotein levels and the risk of SIDS, which may be me

230 atients were followed with CT scan and alpha-fetoprotein levels every 3 months for 2 years posttransp

231 tein, 85% were found to have declining alpha-fetoprotein levels from a pretreatment mean of 1405 to 3

232 2.7 per 10,000 births among women with alpha-fetoprotein levels in the lowest quintile and 7.5 per 10

233 creased aspartate aminotransferase and alpha-fetoprotein levels were associated with HCC (p < 0.001).

234 ferase/alanine aminotransferase ratio, alpha-fetoprotein levels, and IL28B single-nucleotide polymorp

235 Program components, Child-Pugh class, alpha-fetoprotein levels, and percentage of tumor replacement.

236 rs of tumor aggressiveness (high serum alpha-fetoprotein levels, P = 0.038; satellite nodules, P < 0.

237 6:0)], where it correlated with plasma alpha-fetoprotein levels.

238 of cellular differentiation, and serum alpha-fetoprotein levels.

239 of a relatively stable genome and low alpha-fetoprotein levels.

240 CE, as measured by imaging studies and alpha-fetoprotein levels.

241 shrinkage and serial decrease of serum alpha-fetoprotein levels.

242 The albumin-alpha-fetoprotein locus epitomizes the main features of transc

243 e genome, downstream of H19 and at the alpha-fetoprotein locus on chromosome 5.

244 nserted into the normally nonimprinted alpha fetoprotein locus.

245 should be screened with ultrasound and alpha-fetoprotein measurement every 6 months.

246 ance for HCC is by ultrasonography and alpha-fetoprotein measurements every 6-12 months.

247 es (Model for End-Stage Liver Disease, alpha-fetoprotein, Milan-Criteria status, and radiological res

248 l response to loco-regional therapies, alpha-fetoprotein modification, inflammatory markers, and leng

249 tients, and follow-up, including serum alpha-fetoprotein monitoring for early detection of malignant

250 from primary resection to recurrence, alpha-fetoprotein more than 100 ng/mL at recurrence, recurrent

251 nodules, albumin less than 3.5 gm/dL, alpha-fetoprotein more than 100 ng/mL, and any vascular invasi

252 rs, tumor size larger than 7.0 cm, and alpha-fetoprotein more than 100 ng/mL.

253 9 transgenic mice had elevated hepatic alpha-fetoprotein mRNA as early as 2 months of age, and hepato

254 (mRNA) levels and reduced Albumin and Alpha-fetoprotein mRNA levels, indicating that they are less d

255 s were greatly elevated maternal serum alpha-fetoprotein (MSAFP) or amniotic fluid alpha-fetoprotein

256 lbumin-positive, transferrin-positive, alpha-fetoprotein-negative) and are able to proliferate in viv

257 euronal cellular adhesion molecule and alpha-fetoprotein, neuroectodermal, and endodermal markers, re

258 Only tumor variables of alpha-fetoprotein, number, total diameter, microvascular invas

259 onseminoma (group A) and elevations of alpha-fetoprotein of 100 ng/mL or greater or of human chorioni

260 ), especially when combined with serum alpha fetoprotein or tumor staging.

261 of either one liver cancer marker, the alpha-fetoprotein, or the detection of Hepatitis C Virus infec

262 reas bridging LRT (P = .03) and serum alpha1-fetoprotein (P = .02) were independent risk factors for

263 the standard HCC serum protein marker alpha fetoprotein (P = 0.57).

264 c acid, suggesting that the high serum alpha-fetoprotein phenotype of G1, associated with the known o

265 Cytokeratin 19-, A6- and alpha-fetoprotein-positive cells within tumors were hepatocyte

266 ng increase in the number of c-kit and alpha-fetoprotein-positive progenitors, without altering album

267 re predominantly H.4 antigen-positive, alpha-fetoprotein-positive, and OV6-negative.

268 Neonatal alpha-fetoprotein prevents circulating estrogens from accessin

269 age 40; p < 0.001), with greater serum alpha-Fetoprotein production (median level: HBV-1000 ng/ml vs.

270 ltaneously stimulated both albumin and alpha-fetoprotein promoters with minimal competition, but surp

271 ivation early in liver development and alpha-fetoprotein reactivation during liver regeneration, but

272 The best alpha-fetoprotein reduction ranged from 32% to 95%.

273 a locus that is unlinked to AFP called Alpha-fetoprotein regulator 1 (Afr1).

274 vel of Gpc3 induction is controlled by alpha-fetoprotein regulator 2 (Afr2).

275 albumin gene family that we have named Alpha-fetoprotein Related Gene (ARG) since it exhibits greates

276 ound no survival benefit with periodic alpha-fetoprotein screening.

277 sing the brain, therefore, to overcome alpha-fetoprotein sequestration of E2, estrogen replacement st

278 An alpha-fetoprotein serum level of 100 ng/mL identified by recei

279 Patients were subdivided according to alpha-fetoprotein serum levels (i.e., normal </= 20 ng/mL; mil

280 Alpha-fetoprotein serum levels have no prognostic meaning in w

281 sons with chronic HBV semiannually for alpha-fetoprotein since 1982.

282 oss of expression of the tumour marker alpha-fetoprotein, the increase in expression of liver cell ma

283 Of 11 patients with elevated alpha-fetoprotein, three (27%) had decreases of 50% or more.

284 er quadruple screening (measurement of alpha-fetoprotein, total human chorionic gonadotropin, unconju

285 clear factor-4alpha (HNF-4) and the alpha(1)-fetoprotein transcription factor (FTF) are activators of

286 ous studies from this laboratory showed that fetoprotein transcription factor (FTF) is required for 1

287 a-hydroxylase promoters mapped to the alpha1-fetoprotein transcription factor (FTF) site in both prom

288 These two DNA elements bind alpha(1)-fetoprotein transcription factor (FTF), a member of the

289 tors, steroidogenic factor-1 (or NR5A1), and fetoprotein transcription factor (or NR5A2) implicated a

290 s recently been shown to interact with alpha-fetoprotein transcription factor and repress cholesterol

291 The alpha(1)-fetoprotein transcription factor FTF is crucial for the

292 Fetoprotein transcription factor, an orphan nuclear rece

293 lear factor 4alpha (HNF-4alpha) and alpha(1)-fetoprotein transcription factor, are required for both

294 Recently, the orphan nuclear receptor fetoprotein transcription factor/cholesterol-7alpha-hydr

295 cluded a favorable post-LRT radiologic/alpha fetoprotein tumor response, longer time interval from LR

296 California at San Francisco criteria, alpha-fetoprotein, up-to-7 criteria, TTV, and platelet count w

297 Increased serum alpha-fetoprotein was a negative prognostic variable.

298 8-mer peptide (EMTOVNOG) derived from alpha-fetoprotein was compared with tamoxifen for activity aga

299 Human alpha-fetoprotein was never expressed, but in some mice, human

300 Combined expression of SCD and alpha-fetoprotein were associated with outcomes of patients wi